Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$37 Mln
P/E Ratio
--
P/B Ratio
2.09
Industry P/E
--
Debt to Equity
0.46
ROE
-2.14 %
ROCE
-157.36 %
Div. Yield
0 %
Book Value
0.33
EPS
-1.08
CFO
$-279.03 Mln
EBITDA
$-310.37 Mln
Net Profit
$-310.53 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Xilio Therapeutics (XLO)
| -21.30 | -6.05 | -34.07 | -42.18 | -50.08 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Xilio Therapeutics (XLO)
| 72.86 | -79.55 | -83.19 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced,... tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Address: 828 Winter Street, Waltham, MA, United States, 02451 Read more
President, CEO & Director
Dr. Rene Russo BCPS, Pharm.D.
President, CEO & Director
Dr. Rene Russo BCPS, Pharm.D.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Xilio Therapeutics Inc (XLO) stood at $ 71 Mln as on 31-Dec-24
The share price of Xilio Therapeutics Inc (XLO) is $0.75 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Xilio Therapeutics Inc (XLO) has given a return of -50.08% in the last 3 years.
Xilio Therapeutics Inc (XLO) has a market capitalisation of $ 37 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Xilio Therapeutics Inc (XLO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Xilio Therapeutics Inc (XLO) and enter the required number of quantities and click on buy to purchase the shares of Xilio Therapeutics Inc (XLO).
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Address: 828 Winter Street, Waltham, MA, United States, 02451
The CEO & director of Dr. Rene Russo BCPS, Pharm.D.. is Xilio Therapeutics Inc (XLO), and CFO & Sr. VP is Dr. Rene Russo BCPS, Pharm.D..
There is no promoter pledging in Xilio Therapeutics Inc (XLO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Xilio Therapeutics Inc. (XLO) | Ratios |
|---|---|
|
Return on equity(%)
|
-214.02
|
|
Operating margin(%)
|
-940.18
|
|
Net Margin(%)
|
-918.05
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Xilio Therapeutics Inc (XLO) was $0 Mln.
$-0.01
(
